On Monday, StemCells Inc (NASDAQ:STEM)’s shares inclined 1.97% to $0.714.
StemCells Inc (STEM) a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, declared that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study(TM) is designed to assess the efficacy of the Company’s proprietary HuCNS-SC(R) platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury with the primary efficacy outcome being the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal cord.
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.
EXACT Sciences Corporation (NASDAQ:EXAS)’s shares gained 4.78% to $30.69.
EXACT Sciences Corporation (EXAS) declared that it will provide a live video webcast and conference call for its Investor & Analyst Day on June 25.
The event will focus on the Exact Sciences’ strong foundation for growth, counting Cologuard and Exact Sciences Laboratories and customer care center; the company’s multi-faceted commercial strategy to continue to drive growth; and its compelling product pipeline, counting the company’s recently declared partnership with The University of Texas MD Anderson Cancer Center to develop a blood test for lung cancer. The agenda features presentations and talk about with company executives and leaders from MD Anderson and Mayo Clinic.
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test comprises proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test.
At the end of Mondays trade, Berkshire Hathaway Inc. (NYSE:BRK.B)‘s shares surged 0.47% to $141.62.
H.J. Heinz Co said that Warren Buffett’s Berkshire Hathaway Inc has become its majority shareholder by exercising a warrant ahead of the ketchup maker’s planned merger with Kraft Foods Group Inc .
In a regulatory filing, Heinz said Berkshire exercised a warrant to acquire about 46.2 million shares for nearly $462,000 this week.
Heinz said the shares represent about 5.4 percent of its outstanding common stock, and that their issuance gives Berkshire a 52.5 percent overall stake.
The warrant was issued in connection with Heinz’s $23 billion acquisition by Berkshire and Brazilian private equity firm 3G Capital in 2013.
Shareholders of Kraft are planned to vote on July 1 on the Heinz merger, which would create one of the world’s largest food and beverage companies.
Heinz owners would get a 51 percent stake in the combined company, which would be known as Kraft Heinz Co.
Berkshire would own about 27 percent of the combined company, but 3G would oversee day-to-day operations.
Kraft brands comprise its namesake cheese, Oscar Mayer cold cuts and Maxwell House coffee. The company has said it anticipates to close the merger a few business days after shareholder approval.
Berkshire Hathaway, Inc. is a publicly owned investment manager. Through its auxiliaries, the firm primarily engages in the insurance and reinsurance of property and casualty risks business. Berkshire Hathaway was founded in 1889 and is based in Omaha, Nebraska.
Mylan NV (NASDAQ:MYL), ended its Monday’s trading session with -0.28% loss, and closed at $71.42.
Mylan NV (MYL) has said it doubts a Teva deal could withstand antitrust scrutiny, though Teva has said it’s willing to make the necessary divestitures. The companies traded barbs again on Monday, with Mylan pressing Teva for a legally binding offer and Teva maintaining that its proposal is serious.
Teva, for its part, has about 40 injectable drugs and Mylan about 70. If there’s overlap to be sold, Shandell said he wants some of the pieces.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
